证券代码：301115 证券简称：联检科技 公告编号：2025-062 （一）审议通过《关于使用部分超募资金、闲置募集资金及自有闲置资金进 行现金管理的议案》 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 联检（江苏）科技股份有限公司（以下简称 "公司"）第五届董事会第二十 四次会议于2025年9月22日在公司会议室以现场方式召开。本次会议已于2025年9月 19日通过邮件、电话或专人送达的方式通知全体董事、监事、高级管理人员。本次 会议由董事长杨江金先生主持，会议应参加董事9名，实际出席董事9名，全体监 事和高级管理人员列席会议。本次会议的召集、召开方式和程序符合《公司法》 等法律法规及《公司章程》的有关规定。 经与会董事审议，以记名投票表决方式，通过如下决议 ： 经审议，为提高资金的使用效率，会议同意在确保公司正常经营、不影响募 集资金投资计划正常进行和保证资金安全的情况下，使用不超过人民币100,000万 元（含本数）的部分超募资金及暂时闲置募集资金、使用不超过人民币20,000万 元（含本数）自有闲置资金进行现金管理，适当购买投资期限不超过12个月的 ...

Group 1 - The core viewpoint of the news is that Lianjian Technology has shown a positive performance in terms of stock price and financing activities, indicating potential investor interest and market confidence [1][2]. - On September 11, Lianjian Technology's stock price increased by 1.09%, with a trading volume of 48.48 million yuan. The net financing purchase on that day was 877,500 yuan, with a total financing and securities balance of 37.07 million yuan, which is 1.69% of the circulating market value [1]. - The financing balance is currently low, below the 20th percentile level of the past year, while the securities lending balance is at a high level, exceeding the 90th percentile of the past year [1]. Group 2 - As of June 30, Lianjian Technology had 21,600 shareholders, an increase of 0.87% from the previous period, with an average of 4,892 circulating shares per person, a decrease of 0.86% [2]. - For the first half of 2025, Lianjian Technology achieved an operating income of 641 million yuan, representing a year-on-year growth of 7.93%, and a net profit attributable to the parent company of 24.91 million yuan, up 37.75% year-on-year [2]. - Since its A-share listing, Lianjian Technology has distributed a total of 253 million yuan in dividends [3].

9月1日，联检科技涨1.42%，成交额5048.34万元。两融数据显示，当日联检科技获融资买入额389.25万 元，融资偿还303.21万元，融资净买入86.04万元。截至9月1日，联检科技融资融券余额合计3486.86万 元。 融资方面，联检科技当日融资买入389.25万元。当前融资余额3486.86万元，占流通市值的1.61%，融资 余额低于近一年10%分位水平，处于低位。 分红方面，联检科技A股上市后累计派现2.53亿元。 责任编辑：小浪快报 融券方面，联检科技9月1日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，联检(江苏)科技股份有限公司位于江苏省常州市木梳路10号，成立日期2003年3月19日，上 市日期2022年8月31日，公司主营业务涉及建设综合技术服务(建筑工程质量检测与咨询、建筑物(构筑 物)结构检测及其改造(加固)、地下空间建设安全咨询与服务等)以及研发、生产、销售新型建筑材料。 截至6月30日，联检科技股东户数2.16万，较上期增加0.87%；人均流通股4892股， ...

Group 1 - The company, Lianjian Technology, announced on September 4 that it is pursuing an external growth strategy through precise mergers and acquisitions [2] - The company employs a three-dimensional merger strategy of "regional penetration + track expansion + qualification enhancement" to achieve targeted acquisitions [2] - The company prioritizes acquiring regional leaders, high-growth sectors driven by policy, and scarce qualification targets to quickly gain regional qualifications, customer resources, and laboratory networks [2] Group 2 - The company aims to seize high-growth sectors such as water conservancy, automotive, metrology calibration, and low carbon through mergers and acquisitions [2] - The company enhances its specialized qualifications and business capabilities in relevant fields through these acquisitions [2] - The company integrates resources using a "headquarters empowerment + regional autonomy" model, providing a digital management system and sharing customer resources while maintaining the stability of core teams [2]

Core Viewpoint - The company, Lianjian Technology, has extensive experience in the construction industry, focusing on building inspection, testing, and evaluation, and is well-equipped to provide integrated solutions for structural safety and quality enhancement [2]. Group 1: Company Expertise and Services - The company has qualifications for structural testing and can conduct various engineering quality inspections and structural evaluations, as well as real-time monitoring of building safety [2]. - It emphasizes the development of quality assurance and enhancement services for existing buildings and municipal infrastructure, particularly in urban renewal and renovation projects [2]. - The company has established research collaborations with institutions such as the Beijing Residential Building Design Institute and the Jiangsu Architectural Vocational and Technical College to study housing safety and insurance systems [2]. Group 2: Achievements and Recognition - The company has received several honors, including being recognized as an excellent unit in the Jiangsu construction engineering quality testing industry and a 3A-rated enterprise for evaluation and consulting [2]. - It has participated in numerous judicial evaluations and has provided professional testing and evaluation reports for various cases, gaining significant project experience across different building types [2]. - Since 2022, the company has been involved in safety inspections of self-built houses across multiple provinces, receiving consistent recognition from local governments for its contributions [2].

Group 1: Company Operations and Acquisitions - The company has officially entered the automotive testing field through the acquisition of Guanbiao Testing, which provides comprehensive testing services for automobiles and components, enhancing its capabilities in various areas such as material, environmental reliability, electrical performance, and electromagnetic compatibility (EMC) [2] - Guanbiao Testing has obtained third-party testing qualifications from major automotive manufacturers including Geely, Chery, and NIO, expanding its recognition in both traditional and new energy vehicle sectors [2] - The company employs a three-dimensional acquisition strategy focusing on "regional penetration + track expansion + qualification enhancement" to achieve precise mergers and acquisitions, aiming to quickly gain regional qualifications and customer resources [2] Group 2: International Expansion - The company is advancing its global layout in phases, initially focusing on countries along the "Belt and Road" by establishing localized teams to provide tailored testing and certification services [2] - In the mid-term, the company plans to build R&D centers in mature technical standard markets such as Europe and the U.S. to absorb advanced experiences and promote mutual recognition of qualifications [2] - As of now, the company has established regional offices in countries like Vietnam, Thailand, and Indonesia, creating a grid service system that covers "Belt and Road" countries [2] Group 3: Building Safety and Research Initiatives - The company has extensive experience in building safety inspections and has established research collaborations with various institutions to study housing safety management and insurance systems [3] - It has received multiple honors, including being recognized as an excellent unit in construction quality testing in Jiangsu Province and a 3A-rated consulting enterprise [3] - The company has participated in nationwide safety inspections for self-built houses since 2022, covering a wide range of provinces and receiving recognition from local governments [3]

Summary of Key Points Core Viewpoint - On September 3rd, a total of 6 companies had their restricted shares unlocked, with a combined unlocking volume of 1.519 billion shares, amounting to a market value of 7.615 billion yuan based on the latest closing prices [1]. Unlocking Volume - Three companies had unlocking volumes exceeding 10 million shares: Foton Motor (14.29 million shares), Yinos (6.2498 million shares), and Sudar (2.63828 million shares) [1]. Unlocking Market Value - The market value of unlocked shares for three companies exceeded 100 million yuan: Foton Motor (3.986 billion yuan), Yinos (2.514 billion yuan), and Sudar (1.079 billion yuan) [1]. Proportion of Total Share Capital - The unlocking ratio of total share capital for three companies exceeded 10%: Yinos (44.33%), Sudar (34.71%), and Foton Motor (18.04%) [1].

Group 1 - The core viewpoint of the article is that Lianjian Technology (301115) is experiencing stable operational development, as indicated by its financial performance in the first half of 2025 [1] - In the first half of 2025, the company achieved a total operating revenue of 641 million yuan, representing a year-on-year growth of 7.93% [1] - The net profit attributable to the parent company for the same period was 24.91 million yuan, showing a significant year-on-year increase of 37.75% [1]

Core Viewpoint - On September 1, a total of 10 listed companies had their restricted shares unlocked, with a total market value of approximately 5.496 billion yuan [1] Summary by Category Restricted Shares Unlocking - The specific details of the restricted shares unlocking are as follows: - Qingxin Environment (002573): 8.2485 million shares from equity incentive restrictions - Jianke Co., Ltd. (301115): 16.1265 million shares from pre-issue restrictions - Naer Co., Ltd. (002825): 1.2133 million shares from equity incentive restrictions - Guanghetong (300638): 0.5158 million shares from equity incentive restrictions - Liren Technology (001259): 51.66 million shares from pre-issue restrictions - Xutian Salt Industry (600929): 5.295 million shares from equity incentive restrictions - Hanyi Co., Ltd. (301270): 25.9384 million shares from pre-issue restrictions - Wuzhou Special Paper (605007): 1.1687 million shares from equity incentive restrictions - Wufangzhai (603237): 52.9543 million shares from pre-issue restrictions - Aotwei (688516): 16.1989 million shares [1]

Investment Rating - The report provides a positive outlook on the MASH non-invasive diagnosis technology, suggesting it could accelerate new drug development in the pharmaceutical and biotechnology sector [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.65% from August 25 to August 29, underperforming compared to the Wind All A index (1.9%) and the CSI 300 index (2.71%). Only the medical research outsourcing (4.9%) and other biological products (0.14%) sectors saw gains, while in vitro diagnostics (-4.12%), raw materials (-3.34%), and vaccines (-0.59%) faced significant declines [2][7]. - The FDA has accepted the proposal for using VCTE-LSM as a reasonable alternative endpoint for clinical trials in adults with MASH and moderate to advanced fibrosis. This non-invasive method is expected to enhance patient compliance and could lead to a surge in drug development in the MASH area within the next two to three years [2][13]. - The report emphasizes the potential for domestic companies in China to leverage their cost advantages and forward-looking strategies in the field of non-invasive companion diagnostics, particularly in the MASH drug development competition [2]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance was notably weaker than the broader market indices, with specific sub-sectors like medical research outsourcing and other biological products showing resilience [7][8]. - Individual stocks such as Tianchen Medical (30.1%), Ailis (25.6%), and Maiwei Biotech-U (22.4%) performed well, while stocks like Lifang Pharmaceutical (-13.9%), Yuekang Pharmaceutical (-11.9%), and Kanghua Biotech (-11.1%) faced significant losses [10][12]. Industry News and Key Company Announcements - On August 28, Kangfang Biotech announced that its drug AK112 received approval for treating advanced non-squamous non-small cell lung cancer, with promising clinical trial results expected to be presented at an international conference [12]. - The report highlights various companies' financial performances, with notable revenue changes and profit margins, indicating a mixed outlook across the sector [16][17].